Derived neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio may be better biomarkers for predicting overall survival of patients with advanced gastric cancer.

BACKGROUND AND OBJECTIVES: Preoperative systemic inflammatory response and nutritional status play important roles in the tumorigenesis, progression, and prognosis of gastric cancer (GC). This research is designed to investigate the prognostic value of the biomarkers including the neutrophil to lymphocyte ratio (NLR), derived neutrophil to lymphocyte ratio (dNLR), monocyte to lymphocyte ratio (MLR), platelet to lymphocyte ratio (PLR), and prognostic nutritional index (PNI) in predicting overall survival in patients with GC.
METHODS: A total of 1,990 consecutive GC patients who underwent gastrectomy from 2007 to 2011 were enrolled and divided into high level and low level based on the optimal cut-off points for NLR, dNLR, MLR, PLR, and PNI, respectively. The clinicopathological characteristics of the two levels were comparatively analyzed. Overall survival analysis was executed using these biomarkers and clinicopathological characteristics.
RESULTS: The number of metastatic lymph nodes, distant metastasis, American Joint Committee on Cancer TNM stage, radicality, tumor size, metastatic lymph nodes ratio, ascites, and Hb were all significantly associated with NLR, dNLR, MLR, PLR, and PNI. All of these five biomarkers were closely associated with overall survival in univariate analyses, but only dNLR and MLR were significant in multivariate model. dNLR and MLR can be bonded to predict survival, but whether separate or together, dNLR and MLR were mainly significant in advanced stages.
CONCLUSION: Although preoperative NLR, dNLR, MLR, PLR, and PNI in peripheral blood proved significant prediction of prognoses of postoperative GC patients, dNLR and MLR may be better biomarkers for predicting overall survival, especially in advanced GC patients.

Introduction

Gastric cancer (GC) is a very common malignant tumor throughout the world, and it leads to cancer-related mortality rates that are higher than those of many other tumors.1 Although efforts toward early diagnoses and treatment for GC have made great progress, and we can frequently perform radical surgery for GC, the prognoses for patients with advanced GC are still very poor, and their 5-year survival rate remains in an unsatisfactory range of 10%–15%.2 To improve the treatment of GC patients, developing prognostic indicators is critical for improving therapeutic decision-making.

Several lines of research have reported that the immune system plays a crucial role in controlling tumor growth, and neutrophils, lymphocytes, monocytes, and platelets are important for the tumor-induced systemic inflammatory response (SIR).3,4 The SIR may accelerate tumor development and distant metastases through several mechanisms, such as promoting secretion of inflammatory mediators and cytokines, inhibiting the apoptosis, and damaging the DNA of tumor cells.5 Biochemical markers, neutrophils, lymphocytes, monocytes, and platelets can be used to evaluate the host antitumor immune responses and effectively predict cancer prognoses.3

In addition, some reports indicate that a “prognostic nutritional index” (PNI) derived from preoperative blood is a gauge of nutritional status that is also associated with the mortality of GC patients.6 In this study, we sought clinicopathological characteristics that affected these biomarkers and investigated the relationship of these biochemical markers to the survival of GC patients.

Materials and methods

Patients

A total of 1,990 consecutive patients with histologically proven GC patients, aged 19–88 (mean age: 62 years), were recruited as subjects for this study. They had gastrectomies performed in the Harbin Medical University Cancer Hospital (Heilongjiang, People’s Republic of China) between January 2007 and December 2011. All of these patients had preoperative pathological diagnoses through electronic gastroscopies, and the pathological staging was based on the 7th edition of the TNM-classification given by the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC). Patients were not allowed to eat or drink after 10 PM on the first day they were admitted to hospital, and blood samples were acquired before 6 AM the next day and sent to the clinical laboratory for immediate analysis of standard clinical tests. The inclusion criteria were as follows: 1) All patients who underwent total or subtotal gastrectomy, 2) radical surgery (R0 with clear margins) patients underwent D2+ lymph nodes resection, while R1 or R2 surgery patients (with residual cancer postoperatively) did not. 3) None of these patients received preoperative neoadjuvant chemotherapy, radiotherapy, or any other antitumor therapies. 4) None of these patients died during a perioperative and a postoperative follow-up time that was longer than 2 months. 5) None of these patients received transfusions before blood tests and none were infected. 6) All of the patients died of GC or GC-related diseases. 7) All of the patients signed written informed consent on the day they were admitted to the hospital to allow the use of their data for any future study. The research project was approved by the Medical Ethics Committee of the Harbin Medical University Cancer Hospital. The clinical characteristics of the 1,990 study subjects with GC are summarized in Table 1.

Table 1

Characteristic of GC patients

Variable	N (%)
Sex
Female	523 (26.3)
Male	1,467 (73.7)
Age (year)
≤62	1,232 (61.9)
>62	758 (38.1)
Tumor depth
T1	124 (6.2)
T2	187 (9.4)
T3	512 (25.7)
T4	1,167 (58.7)
Lymph nodes
N0	460 (23.1)
N1	343 (17.2)
N2	447 (22.5)
N3	740 (37.2)
Metastasis
M0	1,781 (89.5)
M1	209 (10.5)
AJCC stage
I	162 (8.1)
II	476 (23.9)
III	1,143 (57.5)
IV	209 (10.5)
Radicality
R0	1,468 (73.8)
R1 or R2	522 (26.2)
Tumor size (cm)
≤6	1,290 (64.8)
>6	700 (35.2)
Location
Upper	273 (13.7)
Middle	371 (18.6)
Low	1,160 (58.3)
Whole	186 (9.4)
MLNRa
≤31.5%	1,155 (58.0)
>31.5%	835 (42.0)
Differentiationb
Differentiated	322 (16.2)
Undifferentiated	1,668 (83.8)
Ascites
No	1,912 (96.1)
Yes	78 (3.9)
CA19–9 (U/mL)
≤37	1,556 (78.2)
>37	434 (21.8)
CEA (ng/mL)
≤5	1,527 (76.7)
>5	463 (23.3)
Hb (g/L)
≤130	1,014 (51.0)
>130	976 (49.0)
Tobacco
Yes	985 (49.5)
No	1,005 (50.5)
dNLR
≤1.73	1,206 (60.6)
>1.73	784 (39.4)
MLR
≤0.22	917 (46.1)
>0.22	1,073 (53.9)
NLR
≤2.10	1,018 (51.2)
>2.10	972 (48.8)
PLR
≤139.12	908 (45.6)
>139.12	1,082 (54.4)
PNI
≤51.07	960 (48.2)
>51.07	1,030 (51.8)

Notes:

The average point of MLNR was 31.5%.

Grades1 and 2 were differentiated, and grades 3 and 4 were undifferentiated.

Abbreviations: AJCC, American Joint Committee on Cancer; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; dNLR, derived neutrophil to lymphocyte ratio; GC, gastric cancer; Hb, hemoglobin; MLNR, Metastatic lymph nodes ratio; MLR, monocyte to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index.

Patients underwent relevant investigation 1 week before surgery. All patients recruited with stage IV cancer were confirmed by pathology of their liver, lung, or peritoneal metastases and complications such as bleeding, perforation, and pyloric obstruction. The standard blood tests obtained on the morning after admission included albumin (g/L), white blood cell count (109/L), neutrophil count (109/L), lymphocyte count (109/L), monocyte count (109/L), platelet count (109/L), carbohydrate antigen 19-9 (CA19-9) (U/mL), and carcinoembryonic antigen (CEA) (ng/mL). The neutrophil to lymphocyte ratio (NLR), derived neutrophil to lymphocyte ratio (dNLR), monocyte to lymphocyte ratio (MLR), platelet to lymphocyte ratio (PLR), and prognostic nutritional index (PNI) were calculated using the following formulas:7–9

NLR = Neutrophil count/Lymphocyte count;

dNLR = Neutrophil count/(White blood cell count - Neutrophil count);

MLR = Monocyte count/Lymphocyte count;

PLR = Platelet count/Lymphocyte count;

PNI = Albumin count + Lymphocyte count × 5.

Patient follow-up

Every patient was followed up regularly until June 2016 or death (In the first 2 postoperative years, it was every 3 months, and in the following several years it was at 6 months intervals). The total duration of follow-up varied from 3 months to 9 years, with a median of 37 months. Overall survival time was calculated as the interval from the surgery to death.

Statistical analysis

The optimal cut-off levels for NLR, dNLR, MLR, and PLR were determined by receiver operating curve (ROC) analysis.10,11 As the optimal cut-off level for PNI did not have statistical significance, we took the average PNI value (51.07) as the cut-off point (Table 2, Figure 1). χ2 tests were used to compare and assess the association between NLR, dNLR, MLR, PLR, and PNI and the subjects’ clinicopatho-logical characteristics. Survival curves were calculated by the Kaplan–Meier method, and the equivalences of survival curves were analyzed using the log-rank test. Multivariate analysis was evaluated by Cox proportional hazards model, and all of the significant characteristics in univariate analysis were carried into multivariate analysis. A P<0.05 was considered statistically significant. All of the statistical analyses were performed using SPSS version 17.0 (IBM Corp., Armonk, NY, USA).

Table 2

The optimal cut-off point for overall survival

Variables	AUC	Cut-off point	P-value
NLR	0.555	2.10	<0.001
dNLR	0.551	1.73	<0.001
MLR	0.554	0.22	<0.001
PLR	0.576	139.12	<0.001
PNI	0.395	–	<0.001

Note: ‘–’ indicates no appropriate cut-off point.

Abbreviations: AUC, area under the curve; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index.

Figure 1

Optimal cut-off points for NLR, dNLR, MLR, PLR, and PNI were applied with ROC curves.

Abbreviations: dNLR, derived neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index; ROC, receiver operating characteristics.

Results

The relationship between clinicopathological characteristics and biomarkers

We calculated the contrasts between the higher and lower biomarker levels of NLR, dNLR, MLR, PLR, and PNI to study the relationship between the different patients’ clinic-pathological characteristics and biomarkers (Table 3). We found that NLR was significantly associated with age, tumor invasion (T), lymph nodes metastasis (N), distant metastasis, TNM stage, surgical radicality, tumor size, metastatic lymph node ratio (MLNR), ascites, CEA, CA19-9, and Hb. dNLR was significantly associated with age, lymph nodes metastasis, distant metastasis, stage, radicality, tumor size, MLNR, ascites, CEA, CA19-9, and Hb. MLR was significantly associated with sex, age, tumor invasion, lymph nodes metastasis, distant metastasis, TNM stage, radicality, tumor size, MLNR, ascites, CEA, CA19-9, and Hb. PLR was significantly associated with sex, tumor invasion, lymph nodes metastasis, distant metastasis, TNM stage, radicality, tumor size, MLNR, ascites, CEA, CA19-9, Hb, and smoking. PNI was significantly associated with tumor invasion, lymph nodes metastasis, distant metastasis, TNM stage, radicality, tumor size, MLNR, ascites, and Hb.

Table 3

Relationship between clinicopathological characteristics and NLR, dNLR, MLR, PLR, and PNI

Factors	NLR			dNLR			MLR			PLR			PNI
	NLR ≤2.10	χ2	P-value	dNLR≤1.73	χ2	P-value	MLR≤0.22	χ2	P-value	PLR≤139.12	χ2	P-value	PNI ≤51.07	χ2	P-value
Sex			0.075			0.143			0.001			<0.001			0.943
Male	733	3.163		875	2.143		643	11.368		706	14.032		707	0.005
Female	285			331			274			202			253
Age (year)			0.01			0.043			<0.001			0.066			0.389
≤62	658	6.572		768	4.076		610	15.338		582	3.388		585	0.743
>62	360			438			307			326			375
Tumor depth			<0.001			0.051			0.001			<0.001			<0.001
T1	79	22.075		83	7.753		75	16.178		84	49.662		36	44.861
T2	118			127			90			112			60
T3	254			309			249			233			265
T4	567			687			503			479			599
Lymph nodes			<0.001			0.025			0.003			<0.001			<0.001
N0	251	21.328		286	9.339		234	14.14		243	25.644		185	30.762
N1	188			221			159			169			159
N2	250			282			221			209			203
N3	329			417			303			287			413
Metastasis			<0.001			0.001			<0.001			<0.001			<0.001
M0	944	23.181		1,101	10.505		855	25.326		837	12.791		831	16.998
M1	74			105			62			71			129
AJCC stages			<0.001			0.003			<0.001			<0.001			<0.001
I	100	31.239		105	13.677		91	32.253		103	43.485		47	46.379
II	263			307			238			246			206
III	581			689			526			488			578
IV	74			105			62			71			129
Radicality			<0.001			<0.001			<0.001			<0.001			<0.001
R0	815	42.615		943	30.955		728	27.764		743	56.056		638	51.226
R1 or R2	203			263			189			165			322
Tumor size (cm)			<0.001			<0.001			<0.001			<0.001			<0.001
≤6	736	51.064		840	31.287		640	18.413		680	74.203		521	90.59
>6	282			366			277			228			439
Location			0.223			0.644			0.14
Upper	140	4.38		170	1.667		108	5.479		128	4.232	0.237	119	4.223	0.238
Middle	172			215			175			158			187
Low	610			705			548			546			557
Whole	96			116			86			76			97
MLNR			<0.001			<0.001			<0.001			<0.001			<0.001
≤31.5%	652	30.88		744	16.758		579	18.167		588	30.943		502	25.167
>31.5%	366			462			338			320			458
Differentation			0.876			0.31			0.68			0.992			0.351
Differentiated	166	0.024		187	1.029		145	0.17		147	<0.001		163	0.871
Undifferentiated	852			1,019			772			761			797
Ascites			<0.001			<0.001			0.038			<0.001			<0.001
No	996	17.114		1,176	16.669		890	4.295		892	20.641		904	18.037
Yes	22			30			27			16			56
CA19–9 (µ/mL)			0.005			0.045			0.017			<0.001			0.17
≤37	822	7.982		961	4.007		739	5.735		742	12.183		738	1.884
>37	196			245			178			166			222
CEA (ng/mL)			<0.001			0.005			0.017			0.007			0.216
≤5	824	20.685		951	7.721		726	5.66		722	7.238		725	1.528
>5	194			255			191			186			235
Hb (g/L)			<0.001			<0.001			<0.001			<0.001			<0.001
≤130	435	56.404		545	40.697		399	25.326		280	270.452		644	193.062
>130	583			661			518			628			316
Tobacco			0.537			0.201			0.992			0.001			0.665
Yes	497	0.381		583	1.636		454	<0.001		488	12.05		480	0.187
No	521			623			463			420			480

Abbreviations: AJCC, American Joint Committee on Cancer; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; dNLR, derived neutrophil to lymphocyte ratio; Hb, hemoglobin; MLNR, metastatic lymph node ratio; MLR, monocyte to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index.

Thus, these tumor-related factors such as lymph node metastases, distant metastasis, AJCC TNM stage, radicality, tumor size, MLNR, ascites, and Hb were all significantly associated with NLR, dNLR, MLR, PLR, and PNI.

The relationship between biomarkers, clinicopathological characteristics, and clinical prognosis

The results revealed that age (>62 years), deeper tumor invasion, more lymph nodes with metastatic involvement, distant metastasis, advanced TNM stage, an R1 or R2 resection (without “clean margins” and leaving residual tumor), larger tumor size (>6 cm), upper tumor location, higher MLNR (>31.5%), undifferentiated neoplasms, ascites, higher CA19-9 levels (>37 U/mL), higher CEA (>5 ng/mL), lower Hb (≤130 g/L), NLR (>2.10), dNLR (>1.73), MLR (>0.22), PLR (>139.12), and PNI (≤51.07) were significantly connected with reduced overall survival time in univariate Kaplan–Meier analyses and log-rank tests (Table 4, Figure 2). The significant factors in the univariate Kaplan–Meier analyses were further studied in multivariate Cox regression model, and our results indicated that age, tumor depth, the number of metastatic lymph nodes, distant metastasis, AJCC TNM stage, radicality, tumor size, MLNR, differentiation, CA19-9, CEA, dNLR, and MLR were significantly associated with overall survival time (P<0.05 for all). Thus, dNLR and MLR were independent risk factors for overall survival time (Table 4).

Table 4

Univariate and multivariate analysis of factors for overall survival

Factors	Univariate	Multivariate
	P-value	HR (95% CI)	P-value
Sex	0.836
Age (year)	<0.001	1.196 (1.071–1.336)	0.002
Tumor depth	<0.001	1.181 (1.066–1.308)	0.001
Lymph nodes	<0.001	1.215 (1.105–1.336)	<0.001
Distant metastasis	<0.001	0.667 (0.508–0.875)	0.004
AJCC stage	<0.001	2.087 (1.698–2.566)	<0.001
Radicality	<0.001	2.140 (1.860–2.463)	<0.001
Tumor size (cm)	<0.001	1.311 (1.164–1.476)	<0.001
Tumor location	<0.001	0.958 (0.899–1.020)	0.180
MLNR	<0.001	1.295 (1.104–1.519)	0.001
Differentiation	<0.001	1.188 (1.018–1.385)	0.029
Ascites	<0.001	1.241 (0.965–1.595)	0.092
CA19–9 (µ/mL)	<0.001	1.218 (1.076–1.378)	0.002
CEA (ng/mL)	<0.001	1.182 (1.045–1.336)	0.008
Hb (g/L)	<0.001	1.004 (0.892–1.130)	0.944
Tobacco	0.376
dNLR	<0.001	1.202 (1.007–1.435)	0.042
MLR	<0.001	1.156 (1.023–1.305)	0.020
NLR	<0.001	0.861 (0.714–1.039)	0.119
PLR	<0.001	0.933 (0.820–1.062)	0.291
PNI	<0.001	0.951 (0.842–1.075)	0.423

Abbreviations: AJCC, American Joint Committee on Cancer; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; dNLR, derived neutrophil to lymphocyte ratio; Hb, hemoglobin; HR, hazard ratio; MLNR, metastatic lymph node ratio. MLR, monocyte to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index.

Figure 2

Kaplan–Meier curves for overall survival according to NLR, dNLR, MLR, PLR, and PNI.

Abbreviations: dNLR, derived neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index.

Then, as the long-term clinical outcomes of dNLR (P<0.001) and MLR (P<0.001) were similar to each other, we tried to study the prognostic value of dNLR and MLR combined together in the whole cohort. We hypothesized that patients with dNLR >1.73 and MLR >0.22 had scores of 2, and dNLR ≤1.73 and MLR ≤0.22 had scores of 0. Patients with dNLR >1.73 and MLR ≤0.22 or dNLR ≤1.73 and MLR >0.22 had score of 1. Figure 3 showed that the overall survival time decreased as the scores increased. We thus found that dNLR combined with MLR could perfectly predict prognoses (P<0.001). Finally, we analyzed the prognostic value of dNLR, MLR, and their combination scores when patients were divided by the AJCC TNM stage. The biomarker dNLR was significant in stages III (P=0.001) and IV (P=0.004), but not in stages I (P=0.263) and II (P=0.676). MLR was significant in stages I (P=0.038) and III (P=0.010), but not in stages II (P=0.208) and IV (P=0.067); the combination score was significant in stages III (P=0.001) and IV (P=0.015), but not in stages I (P=0.165) and II (P=0.484) (Figure 4).

Figure 3

Kaplan–Meier curves for overall survival according to scores of dNLR and MLR.

Abbreviations: dNLR, derived neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio.

Figure 4

Overall survival stratified by TNM stage of dNLR, MLR, and their combination score. A, D, G, and J were stages I, II, III, and IV of dNLR, respectively; B, E, H and K were stages I, II, III, and IV of MLR, respectively; C, F, I, and L were stages I, II, III, and IV of their combination scores.

Abbreviations: dNLR, derived neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio.

Discussion

Pietrzyk et al12 reported that hematological parameters such as NLR and PLR could be used to discriminate GC patients from non-GC patients. It was also reported that SIR had a close relationship with the prognoses of many tumors.13 Inflammation could promote cellular proliferation in neoplasms, stimulate angiogenesis, and lead to lower immunity, thus promoting cancer progression and distant metastases of tumors.14 Many clinical studies have shown that the occurrence and development of GC is closely linked with a chronic SIR.7,15,16 SIR was also reported to be correlated with chemotherapy responses in patients with unresectable GC.17 A few studies showed that PNI as a nutritional status indicator was helpful in predicting survival of patients with GC and many other tumors.9,18,19

A higher NLR, dNLR, MLR, PLR, or lower PNI means elevated neutrophils, monocytes, and platelets or decreased lymphocytes and serum albumin. Neutrophils can secret VEGF (vascular endothelial growth factor), ROS (reactive oxygen species), NO (nitric oxide), interleukin-18, and matrix metalloproteinase and can suppress the tumor-induced T-cell response that promotes tumorigenesis, growth, and metastasis.20 Platelets can accelerate tumor growth by secreting VEGF, which then promotes angiogenesis.21 Lymphocytes, especially CD3+ T-cells, CD8+ T-cells, and NK cells, can inhibit tumorigenesis and kill tumor cells efficiently. A decreased lymphocyte count leads to a decreased anti-tumor response.22,23 Macrophages originating from monocytes can devour tumor cells. This anticancer activity can be augmented when chemokines stimulated by the tumor microenvironment promote macrophage chemotaxis to the neoplastic tissues.24 While albumin levels are used to assess nutritional status and immune function, lower albumin is associated with tumor progression, metastasis, and higher risk of death after surgery.25

Of the clinical factors such as metastatic lymph nodes, distant metastasis, AJCC TNM stage, radical resection, tumor size, MLNR, ascites, and Hb that affect NLR, dNLR, MLR, PLR, and PNI simultaneously, only ascites and Hb were not independent prognostic factors for overall survival. This may suggest that bleeding can lead to increased white blood cell counts and albumin loss that is similar to inflammation and malnutrition, but that this phenomenon was different from the SIR that accompanied tumor appearance and growth. The five biomarkers (NLR, dNLR, MLR, PLR, and PNI) monitored preoperatively in the blood of GC patients have close relationship with the prognoses and overall survival of the patient. Higher NLR, dNLR, MLR, and PLR and lower PNI predicted shorter survival time for GC patients with resectable neoplastic lesions. We have no definite mechanisms to explain these observations, although it has been suggested that this result may be related to the immune microenvironment of the tumor cells.5,26

Our findings for NLR, dNLR, MLR, PLR, and PNI are all derived from routine peripheral blood results of preoperative patients, and they are simple and convenient to use for predicting the prognoses and survival of tumor patients. The GC patients need no additional costly investigations to obtain these risk indicators. However, in our study only dNLR and MLR were independent risk factors for overall survival in the Cox multivariate analysis. Kim et al27 found that NLR was a better indicator than PLR for predicting overall survival. Sakurai et al9 found that PNI was effective for predicting overall survival in elderly and stage I GC patients after gastrectomy. In contrast, our present results failed to confirm the prognostic value of NLR, PLR, and PNI in a Cox multivariate analysis. At the same time, we found that dNLR, MLR, and their combination scores were mainly statistically significant in later stages (III and IV), but not in earlier stages of GC, and the combination scores we derived did not show superior results over dNLR or MLR separately. In spite of this, the SIR may still have been becoming more intense as the tumors progressed, but was not obvious in the initial stages. However, further investigations will be needed to illuminate this phenomenon.

A few limitations of this research should be reviewed. First, this was a retrospective study in a single institution, and some patients were lost to follow-up. Second, GC patients with III/IV stage disease account for 68% of the study population, which may influence the results. Third, some patients with factors such as vascular invasion and postoperative adjuvant chemotherapy, which may affect prognoses to a large extent, were not enrolled according to the study criteria. Therefore, further research will be needed to clarify the relationship between the inflammatory biomarkers and the prognosis of GC patients.

Conclusion

In summary, preoperative NLR, dNLR, MLR, PLR, and PNI in peripheral blood proved to be significant prognostic indicators of the postoperative course of GC patients. Moreover, dNLR and MLR are independent prognostic factors for overall survival and may be better biomarkers in predicting overall survival of patients with GC, especially those with advanced stages of disease. A broad range of institutions should be organized to perform a multicenter study on the prognostic significance of these indicators. Perhaps, in countries like China, which have less developed economies, these readily available and inexpensive biomarkers can be developed to better predict GC prognoses and guide more effective therapeutic strategies.